Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell

Chalk River Isotope Reactor Decommissioning Date Set

Canadian Nuclear Safety Commission renewed Canadian Nuclear Laboratories’ operating license for the Chalk River isotope reactor

The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Laboratories’ (CNL) Nuclear Research and Test Establishment Operating License for the Chalk River Laboratories (CRL) site. as of 2016, it was the world’s largest production reactor for medical nuclear imaging isotopes. However, the decision includes a plan to transition to shutdown and preparation for decommissioning by 2028.  

The decision followed a public hearing Jan. 23–25, 2018. The new license will be valid from April 1, 2018 until March 31, 2028.

CRL is the largest single science and technology complex in Canada, located near Chalk River, Ontario, about 160 km northwest of Ottawa. The National Research Universal (NRU) reactor at Chalk River has been operating at CRL since 1957. Until Oct. 31, 2016, the reactor produced a large percentage of the world's medical isotopes, used in both the diagnosis and treatment of life-threatening diseases. In late 2016, it ended production of molybdenum-99 (Mo-99), the precursor to the making of technetium-99m (Tc-99m), the most widely used radioisotope for single photon emission computed tomography (SPECT) imaging.

The 61-year-old nuclear reactor has had safety concerns requiring shutdowns to make repairs and updates over the past decade. Each time the reactor has shut down, there was a shortage of Tc-99m.  This has prompted the United States government to support plans to create a domestic supply of medical isotopes. In February 2018, the U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) took steps to ensure a stable and secure supply of Tc-99m. The FDA approved the NorthStar Medical Radioisotopes' RadioGenix System used to produce Mo-99. 

Read the FDA approval article “FDA Clears Path for First Domestic Supply of Tc-99m Isotope.”

With the new Canadian reactor licensing agreement, CNL will present a mid-term update in 2023 on its licensed activities at CRL during a public commission meeting within the community. Members of the public will have the opportunity to intervene orally and in writing. CNSC staff will also report annually on CNL’s performance at CRL at a commission meeting with public participation.

The record of decision is available on request to the Commission Secretariat and will be posted on the CNSC website at nuclearsafety.gc.ca. 

For more information: https://www.canada.ca/en/nuclear-safety-commission/news/2018/03/canadian...

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Overlay Init